


Our Vision: To be the Global Leader in Testing for Life

Our Mission: To contribute to a safer and healthier world by providing our customers with innovative and high quality laboratory, research and advisory services whilst creating opportunities for our employees and generating sustainable shareholder value

Our Values: Achievement of our Mission is based on Eurofins "**Core Values**", which commit us to Customer Focus, Quality, Competence & Team Spirit and Integrity

Revenues in EUR million



Eurofins shares are listed on Euronext Paris (since IPO in October 1997)

ISIN FR0000038259, Euronext ERF, Reuters EUFI.PA, Bloomberg ERF FP

Euronext Paris: EURONEXT 100, SBF 120, SBF TOP 80 EW, CAC ALL SHARES, CAC ALL-TRADABLE, CAC HEALTH CARE, CAC L60 RI SW, CAC Large 60, CAC Large 60 EW, CAC NEXT 20, EN H C EQ&SER EW.

Euronext Amsterdam: EN CORE E100 EW, EN EUR N100 EW, EN EUROZONE 150 EW, EN EUROPE 500, EN EUROZONE 300, EN EZ L&M 60 EW.

Other: MSCI Europe, STOXX Europe 600.

Contact and Addresses

Florian Heupel, Group Marketing
info@eurofins.com
 23, Val Fleuri, L-1526 Luxembourg,
 Luxembourg
 Tel +352 261 85 31

Investor Relations
ir@eurofins.com
 Avenue Herrmann Debroux 48, B-1160
 Brussels, Belgium
 Tel +32 2 766 1620

Please refer to our [on-line group directory](#) for laboratory contact information

EUROFINS FACT SHEET

Company Overview

Eurofins Scientific is a Group of independent life sciences companies which provide a unique range of analytical testing services to clients across multiple industries. The Group believes it is the global leader in food, environmental, pharmaceutical and cosmetics products testing and in agrosience CRO services. It is also one of the global independent market leaders in certain testing and laboratory services for genomics, discovery pharmacology, forensics, CDMO, advanced material sciences and in the support of clinical studies. In addition, Eurofins is one of the leading global emerging players in esoteric and molecular clinical diagnostic testing.

History

Eurofins Scientific was founded in 1987 with 4 employees to market the SNIF-NMR® technology, a patented analytical method used to verify the origin and purity of several types of food and beverages and identify sophisticated fraud not detectable by other methods.

Today the Eurofins Group is a leading provider of analytical services with:

- an international network of more than 900 independent companies in over 50 countries generally specialised by end client markets and operating more than **800 laboratories**
- over **48,000** staff
- a portfolio of over **200,000** analytical methods
- more than **400 million** tests performed each year to evaluate the safety, identity, composition, authenticity, origin, traceability, and purity of a wide range of products, as well as providing innovative clinical diagnostic testing services.

Eurofins is one of the fastest growing listed European companies. Since its IPO on the French stock exchange in 1997, Eurofins' revenues have increased by 35% each year (in compound average) to over EUR 4.5 billion in 2019.

Between the Initial Public Offering on 24 October 1997 (€1.83) and 30 June 2020 (€558.6), Eurofins' share price has multiplied by 305x, an annual average increase of 29% (against 3% for the SBF 120, 3% for the CAC 40, 6% for the S&P 500 and 9% for the NASDAQ over the same period).

Recent Developments

In 2019, following two years of intense M&A activity in 2017 and 2018, the Group moved into the final phase of its five year 2016-2020 plan to build a unique global network of state-of-the-art laboratories, market leadership positions, scale and scientific excellence to offer even better, faster, more cost effective and innovative services to its clients. From a financial perspective, this translated into lower investments, in terms of both M&A and Net capex, as well as continued improvement in the profitability of the mature business created or acquired before 2017, leading to improved free cash flow generation.

The Group continued to achieve solid growth of revenues, profits and cash flows in the first half of 2020 in spite of the COVID-19 pandemic. Eurofins employees and scientists have developed testing services, solutions and products that can contribute to supporting over 20 million patients per month.

Having consistently invested at higher rate than any of its large peers in the testing industry, Eurofins has built a very modern, streamlined network of laboratories capable of providing a unique range of high quality analyses at a reasonable cost. In 2019 alone, the Group added another 65,000m² of new or renovated laboratory and office space to its network, and plans to complete an additional 100,000m² of expansion and modernisation of its laboratory network between 2020 and 2021 to bring the surface of its facilities to about 1.5 million m². In addition, Eurofins is developing and deploying advanced IT solutions to manage its laboratories and the very large amounts of data it generates for its clients.

Over the years, Eurofins has developed many new analytical testing methods and has participated in, or led several R&D projects to find better ways to analyse food, the environment, and pharmaceutical products. More recently, the Group has also started to leverage its long standing genomics expertise in the area of specialty clinical diagnostics testing to provide new human diagnostic capabilities. In 2019, despite the major impact of the criminal cyber-attack on Eurofins' operations on 02 June 2019, Eurofins continued to make very good progress towards its operational objectives of building an unmatched state-of-the-art global laboratory infrastructure in its markets. Thanks to this and continued strong organic growth, in 2019 Eurofins has again achieved results in-line with its recently-upgraded objectives and has set new objectives to achieve EUR 5 billion revenues, EUR 1.1 billion adjusted EBITDA and EUR 500 million of free cash flow to the firm in 2020 (Including EUR 100 million revenues contribution from acquisitions).

Future Plans

Eurofins is committed to supporting its clients' objectives of ensuring that their products reach the best possible quality and safety levels in all markets in which they operate and supporting medical practitioners and patients with innovative diagnostic services. The Group intends to continue to develop and acquire the most comprehensive range of state-of-the-art analytical technologies as well as expand its geographical reach in order to support its clients' increasingly stringent quality and safety standards and the expanding demands of regulatory authorities and healthcare practitioners around the world.